Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics Inc (VTGN) is a clinical-stage biopharmaceutical company pioneering neuroscience-focused treatments through innovative stem cell technology. This page provides investors and industry professionals with essential updates on the company’s progress, including press releases, clinical trial milestones, and strategic developments.
Access real-time information on VTGN’s advancements in predictive toxicology, drug metabolism screening, and neuropsychiatric therapies. Our curated news collection ensures you stay informed about regulatory submissions, partnership announcements, and financial disclosures without needing to track multiple sources.
Key updates include progress in stem cell-derived bioassay systems, FDA communications regarding therapeutic candidates, and insights into the company’s unique approach to in vitro testing. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to VTGN’s latest developments. Check back regularly for authoritative reporting on advancements in neuroscience and biotechnology that could shape the future of drug discovery.
VistaGen Therapeutics (NASDAQ: VTGN) has announced a public offering of 63 million shares of common stock at $0.92 each and 2 million shares of Series D preferred stock at $21.16 each, aiming to raise approximately $100 million. The proceeds will support the development of its CNS drug candidates, including PH94B and PH10, as well as other operational costs. The offering is expected to close by December 22, 2020, pending standard conditions. The securities are registered under a previously filed shelf registration statement with the SEC.
VistaGen Therapeutics (NASDAQ: VTGN) announced a public offering of units comprising common stock and Series D convertible preferred stock. The offering, subject to market conditions, aims to raise capital for research and development of its CNS drug candidates, including PH94B, PH10, and AV-101. The preferred stock can convert into common stock pending stockholder approval to increase authorized shares. The company intends to use the proceeds for ongoing clinical and manufacturing expenses, as well as for general corporate purposes.
VistaGen Therapeutics (NASDAQ: VTGN) announced a significant milestone with the Korean Intellectual Property Office granting a patent for PH10, a nasal spray designed to treat major depressive disorder (MDD). This patent extends protection until at least 2034 and complements existing patents in multiple regions including the U.S. and Europe. CEO Shawn K. Singh emphasized that this patent strengthens their global strategy for PH10, especially as MDD impacts over 264 million adults globally, underscoring the urgent need for innovative treatment options.
VistaGen Therapeutics (NASDAQ: VTGN) has appointed Louis Monti, M.D., Ph.D., as Vice President of Translational Medicine, expanding its R&D team. Dr. Monti has worked with the company since 2018 on drug candidates PH94B and PH10, designed to treat anxiety and depression. PH94B has received FDA Fast Track designation and is preparing for Phase 3 trials for social anxiety disorder (SAD). PH10 is set for Phase 2B development for major depressive disorder (MDD). Both candidates show potential as rapid-onset treatments, which could revolutionize the management of these mental health disorders.
VistaGen Therapeutics (NASDAQ: VTGN) reported its fiscal 2021 Q2 financial results for the quarter ending September 30, 2020. The company demonstrated a reduced net loss of approximately $3.7 million, down from $5.7 million in the prior year. Revenue for the quarter was $334,000 associated with a $5 million upfront license payment from EverInsight Therapeutics. R&D expenses decreased significantly to $2.4 million, reflecting the completion of previous clinical studies. VistaGen is advancing its CNS pipeline, preparing for a pivotal Phase 3 study of PH94B for social anxiety disorder set to launch in Q2 2021.
VistaGen Therapeutics (NASDAQ: VTGN) announced new in vitro data showing that PH94B, an intranasal treatment for social anxiety disorder, does not activate GABA-A receptors, differentiating it from benzodiazepines. This suggests that PH94B may avoid common side effects, such as sedation and addiction, making it a safer alternative for treating anxiety. With the FDA's Fast Track designation for PH94B, the company aims to address rising anxiety disorders exacerbated by current societal stressors, moving towards pivotal Phase 3 development.
VistaGen Therapeutics (NASDAQ: VTGN) announced participation in the Guggenheim Healthcare Talks, specifically at the 2nd Annual Neuro/Immunology Day on November 16, 2020. This virtual event will focus on neurological and immunological diseases, highlighting both established and emerging companies. VistaGen is dedicated to developing innovative treatments for anxiety, depression, and other CNS disorders, and is committed to exceeding current treatment standards. For more details, visit www.vistagen.com.
VistaGen Therapeutics (NASDAQ: VTGN) has received a 180-day extension from Nasdaq to regain compliance with its minimum bid price requirement, now having until April 12, 2021. This extension does not impact the company's current listing status on the Nasdaq Capital Market. CEO Shawn K. Singh expressed optimism about regaining compliance while advancing their three CNS drug candidates aimed at addressing anxiety and depression disorders.
VistaGen Therapeutics (VTGN) announced promising data from its second preclinical study of AV-101 combined with probenecid, which may enhance the treatment of central nervous system (CNS) disorders. The study showed that the combination significantly raised brain levels of AV-101's active metabolite, 7-Cl-KYN, improving its therapeutic potential. AV-101, with an excellent safety profile and no significant side effects, could offer a new treatment option for anxiety and depression. The findings could lead to further clinical development under FDA's Fast Track designation for both major depressive disorder and neuropathic pain.
VistaGen Therapeutics (Nasdaq: VTGN), a biopharmaceutical firm focused on CNS disorders, will present at the LD Micro 500 Virtual Conference from September 1-4, 2020. CEO Shawn Singh will speak on September 3 at 11 a.m. EDT. Investors can watch the live webcast by registering online. VistaGen's pipeline includes three drug candidates targeting anxiety and depression, all showing promising safety profiles. The presentation aims to highlight the company's innovative approach to treating CNS disorders and its position within the micro-cap market.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
